CoChat

Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer

Open access
Sokol, E.S., Feng, Y.X., Jin, D.X., Basudan, A., Lee, A.V., Atkinson, J.M., Chen, J., Stephens, P.J., Frampton, G.M., Gupta, P.B., Ross, J.S., Chung, J.H., Oesterreich, S., Ali, S.M., Hartmaier, R.J. · 2019 · Annals of Oncology
Cited by 93

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background: Invasive lobular carcinoma (ILC) as a disease entity distinct from invasive ductal carcinoma (IDC) has merited focused studies of the genomic landscape, but those to date are largely limited to the assessment of early-stage cancers. Given that genomic alterations develop as acquired resistance to endocrine therapy, studies on refractory ILC are needed. Patients and methods: Tissue from 336 primary-enriched, breast-biopsied ILC and 485 estrogen receptor (ER)-positive IDC and metastatic biopsy specimens from 180 ILC and 191 ER-positive IDC patients was assayed with hybrid-capture-based comprehensive genomic profiling for short variant, indel, copy number variants, and rearrangements in up to 395 cancer-related genes. Results: Whereas ESR1 alterations are enriched in the metastases of both ILC and IDC compared with breast specimens, NF1 alterations are enriched only in ILC metastases (mILC). NF1 alterations are predominantly under loss of heterozygosity (11/14, 79%), are mutually exclusive with ESR1 mutations [odds ratio = 0.24, P < 0.027] and are frequently polyclonal in ctDNA assays. Assessment of paired specimens shows that NF1 alterations arise in the setting of acquired resistance. An in vitro model of CDH1 mutated ER-positive breast cancer demonstrates that NF1 knockdown confers a growth advantage in the presence of 4-hydroxy tamoxifen. Our study further identified a significant increase in tumor mutational burden (TMB) in mILCs relative to breast ILCs or metastatic IDCs (8.9% >20 mutations/mb; P < 0.001). Most TMB-high mILCs harbor an APOBEC trinucleotide signature (14/16; 88%). Conclusions: This study identifies alteration of NF1 as enriched specifically in mILC. Mutual exclusivity with ESR1 alterations, polyclonality in relapsed ctDNA, and de novo acquisition suggest a role for NF1 loss in endocrine therapy resistance. Since NF1 loss leads to RAS/RAF kinase activation, patients may benefit from a matched inhibitor. Moreover, for an independent subset of mILC, TMB was elevated relative to breast ILC, suggesting possible benefit from immune checkpoint inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdy497

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 93

Metadata

Authors
Sokol, E. S., Feng, Y. X., Jin, D. X., Basudan, A., Lee, A. V., Atkinson, J. M., Chen, J., Stephens, P. J., Frampton, G. M., Gupta, P. B., Ross, J. S., Chung, J. H., Oesterreich, S., Ali, S. M., & Hartmaier, R. J.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2019-01
Volume
30
Issue
1
Pages
115-123
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2900579069
Cited by
93
References
5
FWCI
1.76
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer. https://app.cochat.ai/papers/10.1093/annonc/mdy497
The paper
Sokol, E. S., Feng, Y. X., Jin, D. X., Basudan, A., Lee, A. V., Atkinson, J. M., Chen, J., Stephens, P. J., Frampton, G. M., Gupta, P. B., Ross, J. S., Chung, J. H., Oesterreich, S., Ali, S. M., & Hartmaier, R. J. (2019). Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mdy497

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.